Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign?
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Inside the spectrum of non-alcoholic fatty liver disease, simple fatty liver is generally thought of as being "non progressive", differently from non-alcoholic steatohepatitis, which increases in severity due to the presence of apoptosis/inflammation and fibrosis. The "benignity" of fatty liver is widely accepted but conceptually difficult to maintain because the mechanisms underlying this entity are the same ones that determine the more severe form.Findings provide evidence that iron overload is associated with increased liver damage and collagen deposition. Transforming growth factor-beta1 released by hepatic stellate cells during chronic liver injury plays a critical role in liver apoptosis and fibrogenesis. OBJECTIVE: To verify whether both the forms of non-alcoholic fatty liver disease were really dissimilar, evaluating the serum profile of two key parameters, indexes of severity. METHODS: A total of 123 patients (57 females) participated, forming three groups: forty five patients with fatty liver, 42 patients with non-alcoholic steatohepatitis and 36 with chronic hepatitis C. All had a biopsy-proven diagnosis. MEASUREMENTS: Serum concentrations of transforming growth factor-beta1 and ferritin. RESULTS: High concentrations of transforming growth factor-beta1 were noticed in patients suffering from both fatty liver and non-alcoholic steatohepatitis, 129.1 (45.4) versus 116.8 (42.2) ng/mL, P = 0.2; they were significantly superior to those of chronic hepatitis C patients 87.5 (39.5) ng/mL, P < 0.001. Ferritin levels were on average above normal values and similar in the three groups (P = 0.9), also when adjusted for gender (P = 0.5) and age (P = 0.3). CONCLUSION: No difference between serum concentrations of transforming growth factor-beta1 and ferritin in fatty liver and non-alcoholic steatohepatitis suggests that these forms share more common aspects, regarding their progression, than previously thought.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890 · cited 1×
“The definition of "benignity" concerning FL is wideaccepted [2] but conceptually difficult to maintain because the mechanisms, i.”
BackgroundHepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis
Feldstein, A. E., Canbay, A., Angulo, P., Taniai, M., Burgart, L. J., Lindor, K. D., & Gores, G. J. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00907-7 · Cited by 1,085 · cited 1×
“It is important to stress that hepatocyte apoptosis is significantly increased in patients with NASH and correlates with disease severity [7].”
BackgroundYoneda, M., Mawatari, H., Fujita, K., Iida, H., Yonemitsu, K., Kato, S., Takahashi, H., Kirikoshi, H., Inamori, M., Nozaki, Y., et al. (2007) · Journal of Gastroenterology · doi:10.1007/s00535-007-2060-x · Cited by 294 · cited 1×
“Further, we failed to confirm the crucial role of CRP in differentiating FL from NASH even though NASH patients revealed the highest concentrations [15].”
Cited by
The Natural Course of Non-Alcoholic Fatty Liver Disease
Calzadilla Bertot, L., & Adams, L. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050774 · Cited by 620
Nonalcoholic Fatty Liver Disease: A Review and Update
Lewis, J. R., & Mohanty, S. R. (2010) · Digestive Diseases and Sciences · doi:10.1007/s10620-009-1081-0 · Cited by 345
Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease
Minno, M. N. D. D. (2012) · World Journal of Gastroenterology · doi:10.3748/wjg.v18.i41.5839 · Cited by 174
Nonalcoholic fatty liver disease: a challenge from mechanisms to therapy.
Tarantino, G., Citro, V., & Capone, D. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm9010015 · Cited by 134
“, advanced fibrosis/liver cirrhosis) without the mediation of inflammation? In keeping with this hypothesis, authors showed that high concentrations of TGF-β1 were found in patients suffering from both fatty liver and NASH, suggesting that these forms share more common aspects regarding their progression than previous…”
ResultHepatic Stellate Cells: Dictating Outcome in Nonalcoholic Fatty Liver Disease
Wiering, L., Subramanian, P., & Hammerich, L. (2023) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2023.02.010 · Cited by 80
Metadata
- Authors
- Tarantino, G., Conca, P., Riccio, A., Tarantino, M., Di Minno, M. N., Chianese, D., Pasanisi, F., Contaldo, F., Scopacasa, F., & Capone, D.
- Venue
- Journal of Translational Medicine
- Published
- 2008-11-27
- Volume
- 6
- Issue
- 1
- Pages
- 72-72
- ISSN
- 1479-5876 (ISSN-L)
- OpenAlex
- W2111696876
- Cited by
- 83
- References
- 4
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? https://app.cochat.ai/papers/10.1186/1479-5876-6-72
- The paper
- Tarantino, G., Conca, P., Riccio, A., Tarantino, M., Di Minno, M. N., Chianese, D., Pasanisi, F., Contaldo, F., Scopacasa, F., & Capone, D. (2008). Enhanced serum concentrations of transforming growth factor-beta1 in simple fatty liver: is it really benign? Journal of Translational Medicine. https://doi.org/10.1186/1479-5876-6-72
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.